The Asia Pacific Autoinjectors market size witnessed significant growth and is expected to grow at a CAGR of around 19.2% during the forecast period (2022-2030).
An autoinjector is a syringe with a spring-loaded needle and a dose of medication already inside. The apparatus activates and delivers a dose-controlled dose of medication when injected into the body in a sliding motion. Autoinjectors are employed to self-administrate epinephrine (to prevent anaphylaxis), migraine patients (to provide rapid pain relief), and medical and emergency treatments. Autoinjectors have several benefits, including lowering the risk of needle-stuck occurrences, lowering the incidence of needle-related anxiety disorders, maintaining consistent dose quality, and contributing to greater efficacy.
Autoinjectors for self-medication have become popular in Japan to promote patient convenience and independence. Rheumatologists often inject biological medications subcutaneously into patients with rheumatoid arthritis. Autoinjectors are commonly used to improve patient convenience and reduce hospital visits. Autoinjectors are convenient for Japanese patients, especially chronic ones. They can take their meds at home, avoiding hospital visits. Convenience boosts patient happiness and encourages drug adherence and disease management.
Oral medications, inhalation devices, and transdermal patches are becoming more popular in Asia-Pacific countries, which may affect autoinjector sales. Patient preferences, technology, and healthcare infrastructure affect this development across therapeutic domains. Oral drugs are popular in Asia-Pacific because they are convenient, easy to administer, and patient-accepted. Oral drugs are more familiar and less invasive than needles. Inhalation devices treat asthma and chronic obstructive pulmonary disease (COPD). Transdermal patches distribute medication slowly, minimizing the need for injections. Cultural influences, technical improvements, increased healthcare access, and governmental backing may explain Asia-Pacific drug delivery preferences. These variables may reduce autoinjector demand by encouraging alternate drug administration systems.
Several large pharmaceutical companies have moved their production centers to countries in the Asia-Pacific area, such as India and China. One example is that a global pharmaceutical business set up a factory in India to make a variety of generic drugs. This move lets the Company take advantage of the cheaper costs and trained workers in the area while also growing its market share.
The Asia Pacific Autoinjectors market is segmented based on therapy, type, end-user, and country.
The market is further segmented by therapy into Anaphylaxis, Rheumatoid Arthritis, Psoriasis, migraines, Cardiovascular-diseases, and others.
The Anaphylaxis segment dominates the market and is expected to grow at a CAGR of 19.6% during the forecast period.
The market is further segmented by type into Disposable, Reusable.
Disposable dominated the market and is expected to register a CAGR of 18.7% over the forecast period.
The market is further segmented by end-user into Hospitals and clinics, home care, and others.
The home care segment dominates the market and is expected to grow at a CAGR of 19.8% during the forecast period.
The market is analyzed by country in China, India, Japan, Australia, South Korea, and the Rest of Asia-Pacific. China dominated the market and is expected to grow at a CAGR of 18.2% during the forecast period.
Due to the increased prevalence of anaphylaxis, chronic and lifestyle-related diseases including diabetes and CVD, and the aging population, Asia-Pacific has the fastest market growth. This region has 60% of the world's diabetics. Patients are higher in China and India. In the future, autoinjectors will have more use due to these diseases' rising prevalence. Due to their convenience of use, even for self-administration, autoinjectors are predicted to grow in popularity. About 50,000 Chinese children and teens under 20 had type 1 diabetes in 2017.
60% of people with diabetes live in Asia, according to the International Diabetes Federation. According to IDF, the Western Pacific region, encompassing China, Japan, Malaysia, Australia, and Indonesia, is among the most populous. By 2035, this region's 138.2 million diabetics will rise to 201.8 million. Japan, Australia, and South Korea lead autoinjector sales in Asia-Pacific. In 2015, the Australian Society of Clinical Immunology and Allergy (ASCIA) reported that Australia and New Zealand had the greatest food allergies, followed by Japan, Singapore, and Thailand.
The worldwide Autoinjectors market has huge development potential due to rising demand and penetration in emerging economies. Asia-Pacific's fastest economic development and increasing legislative measures are attracting autoinjector manufacturers. China and India have huge autoinjector growth potential in the next years. Health insurance awareness will likely grow through healthcare spending and governmental measures to decrease needle-stick injuries. Large populations like China, Brazil, and India lack primary healthcare services.
According to the report, Korea and Japan are the region's biggest autoinjector consumers. Enbrel released autoinjectors in Japan for viral, bacterial, and fungal diseases. TB killed over 2800 individuals in 2017, according to the WHO.
The Economic Cooperation and Development in Korea reported 28,161 and 36,044 new TB cases in 2016 and 2017, respectively, with 2016 incidence and death rates of 77% and 55.2% per 100,000 persons. Thus, the increased number of TB patients in Asia-Pacific is expected to boost autoinjector demand.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
"Find new revenue generation opportunities"